Oxford Nanopore Technologies (LSE:ONT) is set for a busy month of investor engagement. The company said on 4 November that finance chief Nick Keher would take part in a fireside chat at a healthcare conference in New York on 10 November, followed by aMedTechand …
Cambridge-based 4basebio makes synthetic DNA for use in gene therapies and other advanced medicines. Its revenue comes from clinical-stage projects and DNA sales, and it has recently gained GMP accreditation, a requirement for supplying material used in human trials.
H.B. Fuller announced on 24 June 2026 that it would acquire Advanced Medical Solutions, at a reported price of 285 pence per share. The terms valued the shares at about £715 million, or roughly $942 million. The AMS board was reported to have unanimously …
Aptamer Group is based in the UK and develops Optimer binders, synthetic molecules designed to bind to specific targets for use in diagnostics, laboratory tools and therapeutics. It sells discovery services to life sciences customers and increasingly licenses its technology. It describes itself as …
Abingdon Health Plc (LSE:ABDX) is drawing attention on AIM as investors weigh its latest company-specific developments against the longer-term prospects for its contract development andManufacturingof rapid diagnostic tests. This report is dated 9 November 2026 and focuses on the information and operating context available …
Aptamer Group Plc (LSE:APTA) is drawing attention on AIM as investors weigh its latest company-specific developments against the longer-term prospects for its synthetic affinity binders and discovery services for life-science customers. This report is dated 9 November 2026 and focuses on the information and …
Coiled Therapeutics Plc (LSE:COL) is drawing attention on AIM as investors weigh its latest company-specific developments against the longer-term prospects for its biotechnology research and development. This report is dated 9 November 2026 and focuses on the information and operating context available around that …
Eco Animal Health Group PLC (LSE:EAH) is drawing attention on AIM as investors weigh its latest company-specific developments against the longer-term prospects for its veterinary medicines and health products for livestock. This report is dated 9 November 2026 and focuses on the information and …
Fusion Antibodies Plc (LSE:FAB) is drawing attention on AIM as investors weigh its latest company-specific developments against the longer-term prospects for its antibody discovery, engineering and preclinical development services. This report is dated 9 November 2026 and focuses on the information and operating context …
hVIVO plc (LSE:HVO) is drawing attention on AIM as investors weigh its latest company-specific developments against the longer-term prospects for its clinical-trial services, including human challenge studies and laboratory services. This report is dated 9 November 2026 and focuses on the information and operating …